

\*\*\*

**Proposed Proclamation**  
**for**  
**Prostate Cancer Awareness Month**  
**September 2021**



**Proposed Proclamation Supplement**  
**Prostate Cancer Awareness Month – September 2021**

**Table of Contents**

| <b>Page</b> | <b>Subject</b>  |
|-------------|---|
| 1.          | Table of Contents   |
| 2.          | Discussion  |
| 3.          | Proposed Proclamation   |
| 4.          | Reference: ACS Cancer Facts & Figures 2021                        |
| 5.          | Reference: ACS Cancer Facts & Figures 2021                        |
| 6.          | Reference: ACS Cancer Facts & Figures 2021                        |
| 7.          | Reference: ACS Cancer Facts & Figures 2021                        |
| 8.          | Reference: ACS Cancer Facts & Figures 2021                        |
| 9.          | White House Prostate Cancer Awareness Statement                   |
| 10.         | U.S. Senate Prostate Cancer Awareness Resolution (2 pages)        |
| 11.         | California Senate & Assembly Prostate Cancer Awareness Resolution |

The American Cancer Society document Cancer Facts & Figures 2021 is the source document for all of the information in this Proposed Proclamation. It can be found on the ACS website: [www.cancer.org](http://www.cancer.org). In the Search box, type Cancer Facts & Figures 2021. The entire 67-page document is available in a PDF format.

**Prepared by**

Bill Doss  
Director  
California Prostate Cancer Coalition  
4909 Moonshadow Court  
Rocklin, CA 95677  
916-772-2222  
[wdoss@surewest.net](mailto:wdoss@surewest.net)  
[www.prostatecalif.org](http://www.prostatecalif.org)

## Proposed Proclamation Supplement

### Prostate Cancer Awareness Month – September 2021

#### Discussion

The purpose of this Supplement is to assist government agencies issue a Proclamation designating September 2021 as Prostate Cancer Awareness Month. In this Supplement, the word “Resolution” may be substituted for the word “Proclamation” as required by the issuing government body. The proposed Proclamation on page 3 is in keeping with the national historical practice of recognizing September as Prostate Cancer Awareness Month.

The proposed Proclamation on the next page was prepared using statements from the American Cancer Society document “Cancer Facts & Figures – 2021”. There is a page number in parenthesis after each WHEREAS. This page number refers to the location in this Supplement for the source of the WHEREAS. Information on each reference page has been underlined to assist the reader identify the source for each WHEREAS.

There are more than 3.1 million men alive in the USA with a history of prostate cancer. The American Cancer Society estimates that 1 in 8 men will develop prostate cancer in their lifetime. Prostate cancer is the most diagnosed cancer in men and is the second leading cause of cancer deaths in men after lung cancer. Every 17 minutes, 24/7, an American man dies from prostate cancer.

More men are diagnosed with prostate cancer in California than any other state. California also has the highest number of deaths from this disease. It is estimated that this year in the state, 25,880 men will be diagnosed and 4,140 men will die from this disease.

The early stages of prostate cancer usually show no symptoms and there are no self-tests for this disease. Early detection is the key to prostate cancer survival. The 5-year survival rate for prostate cancer approaches 100% if the disease is treated early. The 5-year survival rate drops to 30% if the cancer has metastasized. Treatment options for prostate cancer vary depending on a man’s age, the cancer stage and grade, as well as the patient’s other medical conditions. The patient’s personal values and preferences are also a consideration.

Each year, the President of the United States, The United States Senate, and the Governors of many States issue Proclamations declaring September as Prostate Cancer Awareness Month. Many counties and cities across the country also recognize Prostate Cancer Awareness Month in September by issuing their own Proclamations.

Copies of previous year’s Prostate Cancer Awareness Proclamations from the White House, US Senate, and California Senate and Assembly, are provided at the end of this Supplement for the reader to review the format and phrasing used in other Proclamations.

•••

## Proposed Proclamation

### Prostate Cancer Awareness Month – September 2021

**Note:**

**After each WHEREAS, there is a page reference in this Supplement for the source of each statement**

This is a Proclamation to designate September 2021 as Prostate Cancer Awareness Month.

1 WHEREAS, prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer deaths in men; and (page 4)

2 WHEREAS, the American Cancer Society estimates there will be 248,530 new cases of prostate cancer in the USA in 2021, resulting in an estimated 34,130 deaths; and (page 4)

3 WHEREAS, it is estimated 25,880 men in California will be diagnosed with prostate cancer this year and it is estimated 4,140 California men will die from this disease this year; and (page 5-6)

4 WHEREAS, the incidence of prostate cancer is almost 80% higher in non-Hispanic Black men than in non-Hispanic White men for reasons that remain unclear; and (page 7)

5 WHEREAS, early-stage prostate cancer usually has no symptoms and studies suggest strong genetic predisposition may be responsible for 5%-10% of prostate cancer; and (page 7)

6 WHEREAS, late-stage prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, ribs, or other areas in the body; and (page 7)

7 WHEREAS, the 5-year survival rate approaches 100% when prostate cancer is diagnosed and treated early, but drops to 30% when it spreads to the other parts of the body; and (page 8)



8 WHEREAS, risk factors for prostate cancer are increasing age, African ancestry, a family history of the disease, and certain inherited genetic conditions; and (page 7)

9 WHEREAS, the American Cancer Society recommends that men have a conversation with their health care provider and make an informed decision about whether to be tested for prostate cancer based on their personal values and preferences; and (page 7)

10 WHEREAS, the (name of issuing governing body) joins communities across our nation to increase the awareness about the importance for men to make an informed decision with their health care provider about early detection and testing for prostate cancer, and now, therefore be it

11 RESOLVED, that the (name of issuing government body) designate September 2021 as Prostate Cancer Awareness Month.

Figure 3. Leading Sites of New Cancer Cases and Deaths – 2021 Estimates

|                                | Male                  |                 |        | Female  |                       |   |                 |
|--------------------------------|-----------------------|-----------------|--------|---|-----------------------|---|-----------------|
| Estimated New Cases            | Prostate              | 248,530         | 26%    |  | Breast                | 281,550   | 30%             |
|                                | Lung & bronchus       | 119,100         | 12%    |   | Lung & bronchus       | 116,660   | 13%             |
|                                | Colon & rectum        | 79,520          | 8%     |   | Colon & rectum        | 69,980  | 8%              |
|                                | Urinary bladder       | 64,280          | 7%     |   | Uterine corpus        | 66,570  | 7%              |
|                                | Melanoma of the skin  | 62,260          | 6%     |   | Melanoma of the skin  | 43,850  | 5%              |
|                                | Kidney & renal pelvis | 48,780          | 5%     |   | Non-Hodgkin lymphoma  | 35,930  | 4%              |
|                                | Non-Hodgkin lymphoma  | 45,630          | 5%     |   | Thyroid               | 32,130  | 3%              |
|                                | Oral cavity & pharynx | 38,800          | 4%     |   | Pancreas              | 28,480  | 3%              |
|                                | Leukemia              | 35,530          | 4%     |   | Kidney & renal pelvis | 27,300  | 3%              |
|                                | Pancreas              | 31,950          | 3%     |   | Leukemia              | 25,560  | 3%              |
|                                | All sites             | 970,250         |        |   | All sites             | 927,910   |                 |
|                                | Estimated Deaths      | Lung & bronchus | 69,410 |   | 22%                   |  | Lung & bronchus |
| Prostate                       |                       | 34,130          | 11%    | Breast  | 43,600                |   | 15%             |
| Colon & rectum                 |                       | 28,520          | 9%     | Colon & rectum  | 24,460                |   | 8%              |
| Pancreas                       |                       | 25,270          | 8%     | Pancreas  | 22,950                |   | 8%              |
| Liver & intrahepatic bile duct |                       | 20,300          | 6%     | Ovary   | 13,770                |   | 5%              |
| Leukemia                       |                       | 13,900          | 4%     | Uterine corpus  | 12,940                |   | 4%              |
| Esophagus                      |                       | 12,410          | 4%     | Liver & intrahepatic bile duct  | 9,930                 |   | 3%              |
| Urinary bladder                |                       | 12,260          | 4%     | Leukemia  | 9,760                 |   | 3%              |
| Non-Hodgkin lymphoma           |                       | 12,170          | 4%     | Non-Hodgkin lymphoma  | 8,550                 |   | 3%              |
| Brain & other nervous system   |                       | 10,500          | 3%     | Brain & other nervous system  | 8,100                 |   | 3%              |
| All sites                      |                       | 319,420         |        | All sites   | 289,150               |   |                 |

Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates do not include Puerto Rico or other US territories. Ranking is based on modeled projections and may differ from the most recent observed data.

©2021, American Cancer Society, Inc., Surveillance Research

## Selected Cancers

This section provides information on the occurrence, risk factors, symptoms, early detection, and treatment for the most commonly diagnosed cancers, and may have limited relevance for cancer subtypes. (For information on rare cancers, see the Special Section in *Cancer Facts & Figures 2017* at [cancer.org/statistics](http://cancer.org/statistics).) Cancer trends are generally based on incidence data during 2000 through 2017 from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, and mortality data during 1975 through 2018 from the National Center for Health Statistics. See Sources of Statistics on page 64 for more information.

### Breast

**New cases and deaths:** In the US in 2021, there will be an estimated 281,550 new cases of invasive breast cancer diagnosed in women (Figure 3); 2,650 cases diagnosed in

men; and an additional 49,290 cases of ductal carcinoma in situ (DCIS) diagnosed in women (Table 1). An estimated 44,130 breast cancer deaths (43,600 women, 530 men) will occur in 2021.

**Incidence trends:** From 2008 to 2017, invasive female breast cancer incidence rates increased by about 0.5% per year.

**Mortality trends:** Since its peak in 1989, the female breast cancer death rate had declined by 41% in 2018 because of earlier detection (through screening, as well as increased awareness of symptoms) and improved treatment. This decrease translates to approximately 403,200 fewer breast cancer deaths during this time period than would have been expected in the absence of this progress. However, the pace of the decline has slowed from almost 2% annually during the 2000s to 1% per year from 2013 to 2018.

**Table 2. Estimated Number\* of New Cases for Selected Cancers by State, US, 2021**

| State                | All sites        | Female breast  | Uterine cervix | Colon & rectum | Uterine corpus | Leukemia      | Lung & bronchus | Melanoma of the skin | Non-Hodgkin lymphoma | Prostate       | Urinary bladder |
|----------------------|------------------|----------------|----------------|----------------|----------------|---------------|-----------------|----------------------|----------------------|----------------|-----------------|
| Alabama              | 30,830           | 4,460          | 250            | 2,470          | 820            | 870           | 4,520           | 1,590                | 1,080                | 4,020          | 1,300           |
| Alaska               | 3,190            | 520            | †              | 330            | 100            | 100           | 370             | 110                  | 110                  | 440            | 160             |
| Arizona              | 39,640           | 5,850          | 300            | 3,060          | 1,290          | 1,110         | 4,550           | 2,900                | 1,690                | 4,680          | 1,910           |
| Arkansas             | 17,980           | 2,370          | 160            | 1,500          | 540            | 520           | 2,970           | 930                  | 680                  | 2,470          | 780             |
| California           | 187,140          | 30,730         | 1,720          | 15,880         | 7,470          | 5,830         | 17,760          | 11,450               | 8,510                | 25,880         | 7,730           |
| Colorado             | 28,630           | 4,580          | 200            | 2,140          | 930            | 870           | 2,570           | 2,240                | 1,090                | 3,920          | 1,230           |
| Connecticut          | 22,910           | 3,540          | 120            | 1,560          | 860            | 650           | 2,750           | 1,300                | 1,010                | 3,160          | 1,180           |
| Delaware             | 7,090            | 990            | †              | 490            | 250            | 200           | 910             | 430                  | 290                  | 900            | 320             |
| Dist. of Columbia    | 3,450            | 630            | †              | 270            | 140            | 80            | 360             | 120                  | 110                  | 550            | 110             |
| Florida              | 148,010          | 20,160         | 1,260          | 11,220         | 4,870          | 6,660         | 18,470          | 9,680                | 8,440                | 19,950         | 6,870           |
| Georgia              | 58,060           | 8,770          | 490            | 4,840          | 1,820          | 1,840         | 7,250           | 3,800                | 2,100                | 8,550          | 2,150           |
| Hawaii               | 7,570            | 1,390          | 60             | 710            | 360            | 200           | 930             | 460                  | 330                  | 880            | 300             |
| Idaho                | 10,240           | 1,410          | 70             | 740            | 330            | 350           | 1,060           | 860                  | 450                  | 1,260          | 500             |
| Illinois             | 74,980           | 11,190         | 560            | 6,200          | 2,710          | 2,120         | 9,600           | 4,030                | 3,010                | 10,250         | 3,320           |
| Indiana              | 39,010           | 5,460          | 290            | 3,310          | 1,300          | 1,150         | 5,960           | 2,310                | 1,570                | 4,260          | 1,830           |
| Iowa                 | 20,000           | 2,710          | 120            | 1,570          | 700            | 740           | 2,610           | 1,290                | 890                  | 2,530          | 880             |
| Kansas               | 16,980           | 2,380          | 100            | 1,440          | 530            | 570           | 2,160           | 940                  | 690                  | 2,420          | 710             |
| Kentucky             | 30,270           | 3,820          | 200            | 2,540          | 910            | 870           | 4,970           | 1,740                | 1,130                | 3,710          | 1,270           |
| Louisiana            | 27,880           | 4,020          | 240            | 2,440          | 720            | 850           | 3,910           | 1,130                | 1,110                | 3,990          | 1,120           |
| Maine                | 10,090           | 1,430          | 50             | 700            | 380            | 330           | 1,530           | 650                  | 430                  | 1,110          | 600             |
| Maryland             | 34,590           | 5,470          | 220            | 2,550          | 1,260          | 980           | 4,230           | 1,870                | 1,360                | 5,020          | 1,320           |
| Massachusetts        | 42,750           | 6,650          | 210            | 2,940          | 1,500          | 1,000         | 5,550           | 2,530                | 1,730                | 5,290          | 2,080           |
| Michigan             | 62,150           | 8,700          | 380            | 4,690          | 2,240          | 1,800         | 8,590           | 3,440                | 2,620                | 8,940          | 3,010           |
| Minnesota            | 33,260           | 4,850          | 160            | 2,490          | 1,210          | 1,380         | 3,970           | 1,850                | 1,520                | 4,020          | 1,520           |
| Mississippi          | 18,750           | 2,550          | 160            | 1,670          | 500            | 510           | 2,870           | 750                  | 630                  | 2,380          | 700             |
| Missouri             | 37,390           | 5,490          | 250            | 2,930          | 1,280          | 1,180         | 5,570           | 1,840                | 1,500                | 4,280          | 1,640           |
| Montana              | 6,930            | 950            | †              | 500            | 210            | 240           | 810             | 510                  | 310                  | 750            | 340             |
| Nebraska             | 11,180           | 1,560          | 80             | 950            | 360            | 390           | 1,350           | 670                  | 460                  | 1,420          | 510             |
| Nevada               | 16,970           | 2,490          | 160            | 1,400          | 480            | 530           | 2,080           | 1,000                | 740                  | 2,090          | 790             |
| New Hampshire        | 9,560            | 1,340          | 50             | 670            | 380            | 270           | 1,240           | 770                  | 410                  | 1,180          | 560             |
| New Jersey           | 56,360           | 8,330          | 420            | 4,250          | 2,260          | 1,840         | 5,900           | 2,570                | 2,460                | 8,120          | 2,620           |
| New Mexico           | 10,970           | 1,640          | 90             | 860            | 410            | 350           | 960             | 680                  | 460                  | 1,350          | 430             |
| New York             | 120,200          | 17,540         | 920            | 8,920          | 4,810          | 4,110         | 13,950          | 4,290                | 5,480                | 15,840         | 5,610           |
| North Carolina       | 63,930           | 9,850          | 430            | 4,650          | 2,110          | 2,050         | 8,830           | 4,250                | 2,480                | 8,970          | 2,650           |
| North Dakota         | 4,200            | 570            | †              | 350            | 140            | 170           | 490             | 250                  | 190                  | 560            | 200             |
| Ohio                 | 73,320           | 10,450         | 500            | 5,860          | 2,750          | 1,930         | 10,350          | 4,610                | 2,890                | 9,010          | 3,330           |
| Oklahoma             | 22,820           | 3,230          | 200            | 1,900          | 660            | 760           | 3,300           | 1,110                | 900                  | 2,710          | 920             |
| Oregon               | 24,790           | 3,870          | 160            | 1,810          | 930            | 720           | 2,990           | 1,710                | 1,070                | 3,130          | 1,270           |
| Pennsylvania         | 85,440           | 12,140         | 560            | 6,670          | 3,290          | 2,690         | 11,170          | 3,690                | 3,840                | 11,160         | 4,260           |
| Rhode Island         | 6,910            | 1,000          | 50             | 490            | 250            | 210           | 950             | 410                  | 310                  | 920            | 370             |
| South Carolina       | 33,030           | 4,990          | 240            | 2,570          | 1,060          | 1,010         | 4,510           | 1,970                | 1,260                | 4,860          | 1,340           |
| South Dakota         | 5,330            | 740            | †              | 450            | 170            | 190           | 650             | 310                  | 230                  | 750            | 240             |
| Tennessee            | 41,980           | 5,850          | 350            | 3,370          | 1,250          | 1,180         | 6,410           | 1,830                | 1,560                | 5,430          | 1,720           |
| Texas                | 133,730          | 20,900         | 1,470          | 11,280         | 4,590          | 4,820         | 15,010          | 4,600                | 5,780                | 14,200         | 4,780           |
| Utah                 | 12,750           | 1,850          | 80             | 900            | 480            | 400           | 770             | 1,610                | 510                  | 1,980          | 480             |
| Vermont              | 4,310            | 610            | †              | 310            | 170            | 110           | 570             | 380                  | 190                  | 430            | 230             |
| Virginia             | 46,340           | 7,450          | 310            | 3,600          | 1,500          | 1,310         | 5,820           | 2,530                | 1,840                | 6,540          | 1,940           |
| Washington           | 42,170           | 6,810          | 310            | 3,140          | 1,320          | 1,290         | 4,780           | 2,730                | 1,870                | 5,370          | 2,000           |
| West Virginia        | 12,500           | 1,610          | 80             | 1,090          | 440            | 410           | 2,020           | 720                  | 530                  | 1,430          | 660             |
| Wisconsin            | 36,520           | 5,210          | 210            | 2,620          | 1,390          | 1,240         | 4,540           | 2,410                | 1,560                | 4,930          | 1,810           |
| Wyoming              | 3,050            | 440            | †              | 230            | 100            | 90            | 320             | 250                  | 130                  | 490            | 150             |
| <b>United States</b> | <b>1,898,160</b> | <b>281,550</b> | <b>14,480</b>  | <b>149,500</b> | <b>66,570</b>  | <b>61,090</b> | <b>235,760</b>  | <b>106,110</b>       | <b>81,560</b>        | <b>248,530</b> | <b>83,730</b>   |

\*Rounded to the nearest 10. Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. Estimates for Puerto Rico are unavailable.  
 †Estimate is fewer than 50 cases. These estimates are offered as a rough guide and should be interpreted with caution. State estimates may not sum to US total due to rounding and exclusion of state estimates fewer than 50 cases.

**Please note:** Estimated cases for additional cancer sites by state can be found in Supplemental Data at [cancer.org/statistics](https://cancer.org/statistics) or via the Cancer Statistics Center ([cancerstatisticscenter.cancer.org](https://cancerstatisticscenter.cancer.org)).

**Table 3. Estimated Number\* of Deaths for Selected Cancers by State, US, 2021**

| State                | All sites      | Brain/<br>nervous<br>system | Female<br>breast | Colon &<br>rectum | Leukemia      | Liver†        | Lung &<br>bronchus | Non-<br>Hodgkin<br>lymphoma | Ovary         | Pancreas      | Prostate      |
|----------------------|----------------|-----------------------------|------------------|-------------------|---------------|---------------|--------------------|-----------------------------|---------------|---------------|---------------|
| Alabama              | 10,590         | 310                         | 720              | 920               | 350           | 470           | 2,860              | 270                         | 220           | 820           | 480           |
| Alaska               | 940            | †                           | 60               | 110               | †             | †             | 180                | †                           | †             | 60            | 50            |
| Arizona              | 12,510         | 410                         | 900              | 1,240             | 490           | 590           | 2,580              | 420                         | 310           | 1,060         | 780           |
| Arkansas             | 6,250          | 140                         | 400              | 500               | 210           | 280           | 1,810              | 200                         | 130           | 450           | 270           |
| California           | 61,860         | 1,990                       | 4,730            | 5,390             | 2,300         | 3,780         | 9,900              | 2,190                       | 1,640         | 4,940         | 4,140         |
| Colorado             | 8,420          | 300                         | 690              | 700               | 300           | 420           | 1,290              | 270                         | 180           | 660           | 560           |
| Connecticut          | 6,400          | 210                         | 420              | 440               | 250           | 320           | 1,350              | 230                         | 160           | 550           | 390           |
| Delaware             | 2,170          | 60                          | 160              | 160               | 90            | 120           | 540                | 80                          | 50            | 190           | 90            |
| Dist. of Columbia    | 1,020          | 70                          | 100              | 90                | †             | 50            | 140                | †                           | †             | 100           | 70            |
| Florida              | 47,170         | 1,370                       | 3,120            | 4,360             | 1,930         | 2,080         | 10,940             | 1,590                       | 1,020         | 3,700         | 2,850         |
| Georgia              | 17,760         | 570                         | 1,410            | 1,700             | 640           | 890           | 4,200              | 550                         | 410           | 1,380         | 1,030         |
| Hawaii               | 2,430          | 60                          | 170              | 230               | 90            | 180           | 540                | 90                          | †             | 230           | 180           |
| Idaho                | 3,230          | 110                         | 250              | 330               | 140           | 140           | 620                | 120                         | 80            | 250           | 200           |
| Illinois             | 23,070         | 680                         | 1,750            | 2,100             | 890           | 1,090         | 4,990              | 770                         | 550           | 2,110         | 1,210         |
| Indiana              | 13,460         | 380                         | 910              | 1,160             | 510           | 610           | 3,520              | 450                         | 290           | 1,030         | 760           |
| Iowa                 | 6,510          | 190                         | 390              | 550               | 260           | 240           | 1,460              | 240                         | 140           | 450           | 440           |
| Kansas               | 5,620          | 180                         | 370              | 500               | 250           | 270           | 1,360              | 190                         | 140           | 420           | 270           |
| Kentucky             | 10,090         | 300                         | 630              | 930               | 390           | 400           | 2,660              | 330                         | 180           | 730           | 440           |
| Louisiana            | 9,380          | 240                         | 670              | 860               | 330           | 610           | 2,360              | 290                         | 240           | 660           | 490           |
| Maine                | 3,390          | 110                         | 190              | 230               | 120           | 130           | 840                | 120                         | 70            | 250           | 160           |
| Maryland             | 11,010         | 310                         | 860              | 1,050             | 430           | 540           | 2,440              | 350                         | 250           | 840           | 640           |
| Massachusetts        | 12,540         | 430                         | 780              | 1,000             | 500           | 640           | 2,770              | 490                         | 310           | 1,070         | 690           |
| Michigan             | 21,260         | 600                         | 1,420            | 1,640             | 800           | 940           | 5,040              | 750                         | 380           | 1,750         | 980           |
| Minnesota            | 10,220         | 350                         | 640              | 850               | 470           | 480           | 1,950              | 400                         | 210           | 820           | 560           |
| Mississippi          | 6,580          | 190                         | 450              | 650               | 270           | 370           | 1,740              | 170                         | 120           | 530           | 340           |
| Missouri             | 12,960         | 340                         | 850              | 1,070             | 510           | 680           | 3,250              | 410                         | 250           | 960           | 630           |
| Montana              | 2,150          | 70                          | 140              | 180               | 80            | 110           | 480                | 70                          | 50            | 160           | 170           |
| Nebraska             | 3,560          | 120                         | 240              | 320               | 160           | 100           | 680                | 120                         | 80            | 290           | 270           |
| Nevada               | 5,410          | 170                         | 400              | 560               | 210           | 270           | 1,080              | 180                         | 130           | 420           | 300           |
| New Hampshire        | 2,840          | 90                          | 170              | 290               | 80            | 120           | 730                | 90                          | 100           | 200           | 150           |
| New Jersey           | 15,870         | 520                         | 1,250            | 1,410             | 640           | 760           | 3,050              | 570                         | 360           | 1,360         | 760           |
| New Mexico           | 3,820          | 110                         | 290              | 350               | 130           | 280           | 560                | 130                         | 110           | 280           | 220           |
| New York             | 33,920         | 990                         | 2,510            | 2,820             | 1,410         | 1,330         | 6,860              | 1,220                       | 870           | 2,920         | 1,880         |
| North Carolina       | 20,150         | 590                         | 1,470            | 1,590             | 760           | 950           | 4,790              | 630                         | 410           | 1,560         | 970           |
| North Dakota         | 1,310          | †                           | 80               | 110               | 60            | 60            | 300                | 50                          | †             | 100           | 70            |
| Ohio                 | 25,140         | 720                         | 1,720            | 2,110             | 960           | 1,130         | 6,180              | 870                         | 390           | 2,000         | 1,450         |
| Oklahoma             | 8,610          | 240                         | 600              | 770               | 310           | 440           | 2,030              | 270                         | 190           | 590           | 400           |
| Oregon               | 8,430          | 270                         | 570              | 650               | 320           | 460           | 1,690              | 310                         | 240           | 690           | 520           |
| Pennsylvania         | 27,960         | 830                         | 1,970            | 2,340             | 1,100         | 1,140         | 6,140              | 980                         | 620           | 2,300         | 1,510         |
| Rhode Island         | 2,140          | 70                          | 120              | 160               | 120           | 120           | 430                | 70                          | †             | 180           | 100           |
| South Carolina       | 10,940         | 360                         | 780              | 880               | 410           | 580           | 2,550              | 320                         | 180           | 860           | 620           |
| South Dakota         | 1,710          | 60                          | 110              | 170               | 60            | 70            | 410                | 60                          | 80            | 130           | 80            |
| Tennessee            | 14,050         | 390                         | 1,070            | 1,220             | 540           | 690           | 3,390              | 480                         | 340           | 1,040         | 710           |
| Texas                | 42,840         | 1,330                       | 3,420            | 4,030             | 1,710         | 2,800         | 8,300              | 1,420                       | 940           | 3,220         | 2,180         |
| Utah                 | 3,470          | 150                         | 300              | 290               | 170           | 160           | 460                | 150                         | 100           | 280           | 240           |
| Vermont              | 1,470          | 60                          | 80               | 130               | 50            | 50            | 340                | 50                          | †             | 110           | 70            |
| Virginia             | 15,550         | 480                         | 1,240            | 1,400             | 580           | 710           | 3,520              | 580                         | 360           | 1,220         | 940           |
| Washington           | 13,130         | 470                         | 940              | 1,020             | 510           | 780           | 2,690              | 470                         | 330           | 1,030         | 850           |
| West Virginia        | 4,580          | 120                         | 290              | 430               | 190           | 210           | 1,190              | 160                         | 90            | 310           | 180           |
| Wisconsin            | 11,700         | 360                         | 750              | 900               | 490           | 490           | 2,490              | 400                         | 260           | 870           | 730           |
| Wyoming              | 990            | 50                          | 70               | 80                | †             | 60            | 210                | †                           | †             | 80            | 50            |
| <b>United States</b> | <b>608,570</b> | <b>18,600</b>               | <b>43,600</b>    | <b>52,980</b>     | <b>23,660</b> | <b>30,230</b> | <b>131,880</b>     | <b>20,720</b>               | <b>13,770</b> | <b>48,220</b> | <b>34,130</b> |

\*Rounded to the nearest 10. †Estimate is fewer than 50 deaths. ‡Liver includes intrahepatic bile duct. These estimates are offered as a rough guide and should be interpreted with caution. State estimates may not sum to US total due to rounding and exclusion of state estimates fewer than 50 deaths. Estimates are not available for Puerto Rico. **Please note:** Estimated deaths for additional cancer sites by state can be found in Supplemental Data at [cancer.org/statistics](https://cancer.org/statistics) or via the Cancer Statistics Center ([cancerstatisticscenter.cancer.org](https://cancerstatisticscenter.cancer.org)).

cancer has usually spread beyond the pancreas when it is diagnosed. For those who do undergo surgery, adjuvant treatment with chemotherapy (and sometimes radiation) may lower the risk of recurrence. For advanced disease, chemotherapy (sometimes along with or followed by a targeted therapy drug) may lengthen survival. Clinical trials are testing several new targeted agents and immunotherapies.

**Survival:** For all stages combined, the 5-year relative survival rate is 10%. Even for the small percentage (11%) of people diagnosed with local disease, the 5-year survival rate is only 39%.

## Prostate

**New cases and deaths:** In 2021, an estimated 248,530 new cases of prostate cancer will be diagnosed in the US and 34,130 men will die from the disease (Table 1). The incidence of prostate cancer is almost 80% higher in non-Hispanic Black men than in non-Hispanic White men for reasons that remain unclear.

**Incidence trends:** Incidence rates for prostate cancer spiked dramatically in the late 1980s and early 1990s, in large part because of a surge in screening with the prostate-specific antigen (PSA) blood test. Likewise, reduced PSA screening, partly because of changes in guidelines, led to an incidence decline beginning around 2000, although the rate has stabilized in recent years (2013-2017).

**Mortality trends:** Prostate cancer death rates declined by about half from the mid-1990s to the mid-2010s due to earlier detection through PSA testing and advances in treatment, but remained stable from 2014 to 2018.

**Risk factors:** Well-established risk factors for prostate cancer are increasing age, African ancestry, a family history of the disease, and certain inherited genetic conditions (e.g., Lynch syndrome and *BRCA1* and *BRCA2* mutations). Black men in the US and the Caribbean have the highest documented prostate cancer incidence rates in the world. Studies suggest that a strong genetic predisposition may be responsible for 5%-10% of prostate

cancers, with another 30%-40% caused by more common gene mutations (higher prevalence) conferring less excess risk (lower penetrance). The only modifiable risk factors are smoking and excess body weight, which may increase risk of aggressive and/or fatal disease.

**Early detection:** Although studies have shown that PSA testing reduces prostate cancer mortality, no major medical organization presently endorses routine screening for men at average risk because of concerns about the high rate of overdiagnosis (detecting disease that would never have caused symptoms or harm), along with the high potential for serious side effects associated with prostate cancer treatment. However, because prostate cancer is a leading cause of cancer death in men, many organizations recommend an “informed decision-making” approach whereby men are educated about screening and encouraged to make a personal choice. The American Cancer Society recommends that beginning at age 50, men who are at average risk of prostate cancer and have a life expectancy of at least 10 years have a conversation with their health care provider about the benefits and limitations of PSA testing and make an informed decision about whether to be tested based on their personal values and preferences. Black men and those with a close relative diagnosed with prostate cancer before the age of 65 should have this discussion beginning at age 45, and men at even higher risk (several close relatives diagnosed at an early age and *BRCA* mutation carriers) should have this discussion beginning at age 40.

**Signs and symptoms:** Early-stage prostate cancer usually causes no symptoms. More advanced disease shares symptoms with benign prostate conditions, including weak or interrupted urine flow; difficulty starting or stopping urination; frequent urination, especially at night; blood in the urine; or pain or burning with urination. Late-stage prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, ribs, or other areas.

**Treatment:** Recent changes in the grading system for prostate cancer have improved tumor characterization and disease management. Careful monitoring of disease progression (called active surveillance) instead of



**Table 8. Five-year Relative Survival Rates\* (%) by Stage at Diagnosis, US, 2010-2016**

|                      | All stages | Local | Regional | Distant |                       | All stages | Local | Regional | Distant |
|----------------------|------------|-------|----------|---------|-----------------------|------------|-------|----------|---------|
| Breast (female)      | 90         | 99    | 86       | 28      | Oral cavity & pharynx | 66         | 85    | 67       | 40      |
| Colon & rectum       | 65         | 90    | 72       | 14      | Ovary                 | 49         | 93    | 75       | 30      |
| Colon                | 63         | 91    | 72       | 14      | Pancreas              | 10         | 39    | 13       | 3       |
| Rectum               | 67         | 89    | 72       | 16      | Prostate              | 98         | >99   | >99      | 30      |
| Esophagus            | 20         | 47    | 25       | 5       | Stomach               | 32         | 70    | 32       | 6       |
| Kidney†              | 75         | 93    | 70       | 13      | Testis                | 95         | 99    | 96       | 73      |
| Larynx               | 61         | 78    | 45       | 34      | Thyroid               | 98         | >99   | 98       | 55      |
| Liver‡               | 20         | 34    | 12       | 3       | Urinary bladder§      | 77         | 69    | 37       | 6       |
| Lung & bronchus      | 21         | 59    | 32       | 6       | Uterine cervix        | 66         | 92    | 58       | 17      |
| Melanoma of the skin | 93         | 99    | 66       | 27      | Uterine corpus        | 81         | 95    | 69       | 17      |

\*Rates are adjusted for normal life expectancy and are based on cases diagnosed in the SEER 18 areas from 2010-2016, all followed through 2017. †Includes renal pelvis. ‡Includes intrahepatic bile duct. §Rate for in situ cases is 96%.

**Local:** an invasive malignant cancer confined entirely to the organ of origin. **Regional:** a malignant cancer that 1) has extended beyond the limits of the organ of origin directly into surrounding organs or tissues; 2) involves regional lymph nodes; or 3) has both regional extension and involvement of regional lymph nodes. **Distant:** a malignant cancer that has spread to parts of the body remote from the primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via the lymphatic system to distant lymph nodes.

**Source:** Howlader N, Noone AM, Krapcho M, et al (eds). *SEER Cancer Statistics Review, 1975-2017*, National Cancer Institute, Bethesda, MD, [https://seer.cancer.gov/csr/1975\\_2017/](https://seer.cancer.gov/csr/1975_2017/), based on November 2018 SEER data submission, posted to the SEER website, April 2019.

©2021 American Cancer Society, Inc., Surveillance Research

(68%) (Table 7), partly reflecting subsite distribution. Studies indicate better survival for patients with HPV-associated cancer.

## Ovary

**New cases and deaths:** In 2021, an estimated 21,410 new cases of ovarian cancer will be diagnosed in the US and 13,770 women will die from the disease (Table 1). Most cases (90%) are epithelial ovarian cancer, the majority of which are high-grade serous tumors, which have the fewest established risk factors and worst prognosis.

**Incidence trends:** The ovarian cancer incidence rate declined by 1% to 2% per year from the mid-1980s through 2017.

**Mortality trends:** The ovarian cancer death rate declined by about 2% per year from 2009 to 2018, a steady trend since the early 2000s.

**Risk factors:** The most important risk factor other than age is a strong family history of breast or ovarian cancer. Women who have certain inherited mutations (e.g., *BRCA1* or *BRCA2* or those related to Lynch syndrome) are at increased risk. Other medical conditions and characteristics associated with increased risk include a

personal history of breast cancer, endometriosis, or pelvic inflammatory disease, and tall adult height. Modifiable factors associated with increased risk include menopausal hormone therapy (estrogen alone or combined with progesterone), previously referred to as hormone replacement therapy or HRT, and excess body weight. Cigarette smoking is associated with a rare subtype (mucinous). Factors associated with lower risk include pregnancy, fallopian tube ligation or removal (salpingectomy), and use of oral contraceptives. Although results from case-control and cohort studies are inconsistent, the weight of the evidence does not support an association between genital exposure to talc-based powder and risk of ovarian cancer.

**Early detection:** Currently, there are no recommended screening tests for ovarian cancer, although clinical trials to identify effective strategies are underway. Women who are at high risk (e.g., *BRCA* or Lynch syndrome mutations) or have symptoms may be offered a thorough pelvic exam in combination with transvaginal ultrasound and a blood test for the CA125 tumor marker, although this strategy has not been proven to reduce ovarian cancer mortality and is associated with serious harms due to a high prevalence of false-positive results.



## **Presidential Message on National Prostate Cancer Awareness Month, 2020**

Issued on: September 1, 2020

During National Prostate Cancer Awareness Month, we call attention to the struggles of men and families affected by prostate cancer, encourage understanding of the most common risk factors and treatments, and celebrate the victories and medical advances that give us hope that one day we will rid our Nation of this disease.

Prostate cancer is the most common form of cancer that affects American men, and nearly 12 percent of men in the United States will be diagnosed with prostate cancer in their lifetime. Each year, more than 200,000 men are newly diagnosed, and more than 30,000 die from this disease. Individuals at the greatest risk for prostate cancer include African American men, men over the age of 65, and men with family histories of prostate or other cancers. While some signs, like trouble urinating and pelvic pain, may indicate the presence of prostate cancer, many men never experience any symptoms. Screening for prostate cancer using the prostate specific antigen test can identify abnormalities and may find cancer early so that affected men can begin treatment before it spreads. For this reason, all men aged 55 to 69 are encouraged to talk to their physicians about screening options.

Thankfully, prostate cancer is treatable, and early detection can help save lives.

My Administration remains committed to ensuring that Americans have access to necessary drugs and therapies to treat prostate cancer, as well as all other diseases they may face. That is why, in July of this year, I signed an Executive Order that eliminates kickbacks to drug company middlemen and passes on massive savings to consumers. This Executive Order will greatly improve prescription drug affordability. We will continue working to make all drugs more affordable to patients, including drugs to treat prostate and other cancers.

This September, we affirm our support for all those battling prostate cancer. Together, we will work to provide every patient with affordable, reliable care, and look toward a future free from the scourge of this disease.

• • •

Ref: <https://www.whitehouse.gov/briefings-statements/presidential-message-national-prostate-cancer-awareness-month-2020/>

File: Whitehouse, 09-01-20 (16 – ACS, Proclamations, 2020), wd



116th CONGRESS – 1st Session

**S. RES. 321**

**Designating September 2019 as National Prostate Cancer Awareness Month**

IN THE SENATE OF THE UNITED STATES

September 19, 2019

**RESOLUTION**

Mr. Menendez (for himself, Mr. Crapo, Mr. Coons, Mr. Van Hollen, Mr. Booker, Mr. Hawley, Mr. Cardin, Mrs. Capito, Mr. Markey, and Mr. Wyden) submitted the following resolution; which was considered and agreed to

Whereas more than 2,900,000 men in the United States live with prostate cancer;

Whereas 1 in 9 men in the United States will be diagnosed with prostate cancer in their lifetimes and 1 in 41 men in the United States will die from prostate cancer;

Whereas prostate cancer is the most commonly diagnosed non-skin cancer and the second-leading cause of cancer-related deaths among men in the United States;

Whereas the American Cancer Society estimates that, in 2019, 174,650 men will be diagnosed with, and more than 31,620 men will die of, prostate cancer;

Whereas 41.9 percent of newly diagnosed prostate cancer cases occur in men under the age of 65;

Whereas the odds of developing prostate cancer rise rapidly after age 50;

Whereas African-American men suffer from a prostate cancer incidence rate that is significantly higher than that of White men and have more than double the prostate cancer mortality rate than that of White men;

Whereas having a father or brother with prostate cancer more than doubles the risk of a man developing prostate cancer, with a higher risk for men who have a brother with the disease and the highest risk for men with several affected relatives;

Whereas screening by a digital rectal examination and a prostate-specific antigen blood test can detect the disease at the earlier, more treatable stages, which could increase the chances of survival for more than 5 years to nearly 100 percent;

Whereas only 30 percent of men survive more than 5 years if diagnosed with prostate cancer after the cancer has metastasized;

Whereas there are no noticeable symptoms of prostate cancer in the early stages, making appropriate screening critical;

Whereas, in fiscal year 2019, the Director of the National Institutes of Health supported approximately \$271,000,000 in research projects focused specifically on prostate cancer;

Whereas ongoing research promises further improvements in prostate cancer prevention, early detection, and treatment; and

Whereas educating people in the United States, including health care providers, about prostate cancer and early detection strategies is crucial to saving the lives of men and preserving and protecting families: Now, therefore, be it

That the Senate

(1) designates September 2019 as National Prostate Cancer Awareness Month;

(2) declares that steps should be taken

(A) to raise awareness about the importance of screening methods for, and treatment of, prostate cancer;

(B) to encourage research

(i) to improve screening and treatment for prostate cancer;

(ii) to discover the causes of prostate cancer; and

(iii) to develop a cure for prostate cancer; and

(C) to continue to consider ways to improve access to, and the quality of, health care services for detecting and treating prostate cancer; and

(3) calls on the people of the United States, interest groups, and affected persons

(A) to promote awareness of prostate cancer;

(B) to take an active role in the fight to end the devastating effects of prostate cancer on individuals, families, and the economy; and

(C) to observe National Prostate Cancer Awareness Month with appropriate ceremonies and activities.

• • •

Ref: <https://www.govtrack.us/congress/bills/116/sres321/text>

File: S. Res 321, 09-19-19



**California Senate Concurrent Resolution Number 142  
Prostate Cancer Awareness Month  
September 2018**

**Introduced by Senator Gaines, May 2, 2018**

**SCR 142 designates  
September 2018 as Prostate Cancer Awareness Month in the State of California.**

**WHEREAS**, Prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer deaths in men; and

**WHEREAS**, The American Cancer Society estimates there will be 164,690 new cases of prostate cancer in the United States in 2018, resulting in an estimated 29,430 deaths; and

**WHEREAS**, It is estimated that 15,190 men in California will be diagnosed with prostate cancer this year, and it is estimated that 3,490 of these men will die from this disease; and

**WHEREAS**, African American men in the United States and Caribbean have the highest documented prostate cancer incidence rates in the world; and

**WHEREAS**, Early prostate cancer usually has no symptoms and studies suggest strong familial predisposition may be responsible for 5 to 10 percent of the disease cases; and

**WHEREAS**, Advanced prostate cancer commonly spreads to the bones, which can cause pain to the hips, spine, ribs, or other areas of the body; and

**WHEREAS**, The five-year survival rate approaches 100 percent when prostate cancer is diagnosed and treated early, but drops to 30 percent when it spreads to other parts of the body; and

**WHEREAS**, Prostate cancer treatment decisions should be based on clinician recommendations and patient values and preferences; and

**WHEREAS**, The American Cancer Society recommends that men should have an opportunity to make an informed decision about whether or not to be tested for prostate cancer based on their personal values and preferences; now, therefore, be it

**Resolved** by the Senate of the State of California, the Assembly thereof concurring, That the Legislature of the State of California hereby proclaims the month of September 2018 as Prostate Cancer Awareness Month in California; and be it further

**Resolved**, That the Legislature joins communities across our nation to increase awareness about the importance for men to make informed decisions with their health care providers about early detection and testing for prostate cancer; and be it further

**Resolved**, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.

• • •